Patients with myocardial bridges should avoid the use of positive inotropic drugs such as digitalis (digoxin, sildenafil, etc.), norepinephrine, and dopamine, as well as nitrates. Myocardial bridging refers to the developmental abnormality of the coronary arteries, which should travel on the surface of the heart, partially penetrating into the myocardium, which can lead to narrowing of the lumen of the coronary arteries, and then myocardial ischemia. During myocardial contraction, the myocardium will squeeze the coronary arteries, aggravating myocardial ischemia and even leading to complete occlusion of the coronary arteries and myocardial infarction. Positive inotropic drugs can enhance myocardial contractility, causing greater compression of the coronary arteries during myocardial contraction and a greater risk of inducing angina pectoris and myocardial infarction, and are therefore contraindicated for use in myocardial bridge patients. In addition, due to the part of the coronary artery located between the myocardium subendothelial tissue development is incomplete, the wall is thin, the use of nitrate drugs, on the contrary, will cause the coronary artery blood reduction, aggravate myocardial ischemia. Therefore, myocardial bridge patients in drug therapy, must be under the guidance of a specialist physician to use drugs, not to self-medication, so as not to cause adverse consequences.